Scott S. Tykodi, MD, PhD | Authors

July 24, 2020

The Seattle Cancer Care Alliance expert discusses key takeaways from cohort a of the KEYTRUDA-427 study, evaluating pembrolizumab monotherapy in patients with clear cell renal cell carcinoma.

July 13, 2020

The Seattle Cancer Care Alliance Expert offered background on cohort A of the KEYNOTE-427 trial.

June 21, 2020

The Seattle Cancer Care Alliance Expert offered background on the first-line use of pembrolizumab monotherapy in advanced clear cell renal cell carcinoma.

February 15, 2015

In this article, we summarize the systemic therapies now available for melanoma, with a focus on the recently approved agents for cutaneous melanoma; discuss important considerations in selecting a treatment from the available options; and highlight some of the promising investigational approaches for this disease.

May 12, 2009

Metastatic melanoma continues to be a challenging disease to treat, with an estimated 8,420 related deaths in the United States in 2008.[1] The 10- year survival rate for patients with metastatic melanoma is less than 10%.[2] More than 3 decades after its initial approval by the US Food and Drug Administration (FDA) in 1975, dacarbazine continues to be the standard of care for most patients with this disease. High-dose interleukin-2 (HD IL-2 [Proleukin]), approved by the FDA in 1998 for metastatic melanoma, benefits a small subset of patients.